Rituximab has been successfully used “off label” to treat diseases driven by B-cell dysregulation, but concerns remain about the safety of using rituximab or similar agents for long periods.
B cells play a key role in many autoimmune diseases, including the immune-mediated neurological disorders neuromyelitis optica (NMO), multiple sclerosis (MS), and myasthenia gravis (MG). Rituximab, which causes short-term depletion of circulating naïve and memory B cells through antibody-dependent cell-mediated cytotoxicity, complement mediated cytotoxicity, and induction of apoptosis, has been successfully used “off label” to treat diseases driven by B-cell dysregulation. The promising results of some studies on the use of rituximab in these disorders has generated interest in further developing B-cell depleting or anti-proliferative agents for use in these indications, but concerns remain about the safety of using rituximab or similar agents for long periods.
A study newly published in PLOS One sought to investigate the long-term safety, incidence of infections, and malignancies in patients receiving continuous therapy with rituximab over periods of 36 months to 7 years. The retrospective study was conducted at 2 tertiary centers in Detroit, Michigan, and Chicago, Illinois, and involved 29 patients with diagnoses of MS (n = 5), NMO (n = 21), or MG (n = 3) who received rituximab at doses of 1000 mg via intravenous administration every 6 to 9 months after an initial course of the drug. The mean duration of treatment was 51.3 months (±12.2 months), and the mean number of rituximab treatment cycles was 8.83 (±2.85).
During the observation period:
The study’s authors concluded that rituximab was well tolerated over time in patients with NMO, MS, and MG; that AEs and SAEs remained low throughout the observation period; and that patients remained clinically stable while receiving continuous rituximab infusions. Though the study was small, it makes an important contribution, say the authors, to documenting the long-term tolerability and efficacy of rituximab as a viable option for the treatment of immune-mediated neurological diseases. Further studies will be needed to corroborate these results.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.